Sanofi Pasteur and MSD have now completed the takedown of their vaccines joint venture Sanofi Pasteur MSD, ending a collaboration that has spanned more than two decades.
The move, announced in March last year, was spurred by the desire of each firm to pursue their own “distinct growth strategies” in the field.
Since its birth in 1994 Sanofi Pasteur MSD launched a number of vaccines onto the European market such as cervical cancer jab Gardasil and shingles vaccine Zostavax, and pulled in sales of some 824 million euros in 2015.
Both partners have now integrated their respective European vaccine businesses back into their operations, enabling them to independently manage their own product portfolios.
